Email this article 
Results of treatment for patients with newly diagnosed Hodgkin lymphoma in the Republic of Sakha (Yakutia)
- Authors: Aleksandrova T.N.1,2, Bosikov I.A.2, Yadrikhinskaya U.V.1, Mulina I.I.1, Yadrikhinskaya V.N.2
-
Affiliations:
- Republican Hospital No. 1 – National Centre of Medicine named after M. E. Nikolaev
- North-Eastern Federal University named after M. K. Ammosov
- Issue: Vol 21, No 1 (2026)
- Pages: 52-58
- Section: HEMATOLOGIC MALIGNANCIES: TREATMENT
- Published: 23.03.2026
- URL: https://oncohematology.eco-vector.com/ongm/article/view/1063
- DOI: https://doi.org/10.17650/1818-8346-2026-21-1-52-58
- ID: 1063
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
Background. Hodgkin lymphoma is one of the highly curable types of cancer, but patients with advanced stages remain at risk of early progression and late chemotherapy effects.
Aim. To evaluate the efficacy of first-line treatment for patients with newly diagnosed Hodgkin lymphoma in the Republic of Sakha (Yakutia).
Materials and methods. We provided a retrospective analysis of 33 patients (17 women and 16 men, median age 42) with newly diagnosed Hodgkin lymphoma, who were treated in 2019–2024 (follow up to 01.06.2025). In the first-line treatment, depending on the stage and prognostic group, the following regimens were used: ABVD (doxorubicin + bleomycin + vinblastine + dacarbazine), BEACOPP-esc, BEACOPP-14 (cyclophosphamide + doxorubicin + etoposide + dacarbazine + bleomycin + vincristine + prednisolone), BV-AVD (brentuximab vedotin + doxorubicin + vinblastine + dacarbazine) and IVDG (idarubicin + vinblastine + dacarbazine + gemcitabine). Statistical analysis performed using programs StatTech v.4.8.5 и R v.4.4.1.
Results. Complete remission was achieved in 27 (87.1 %). Early relapse and progression were observed in 3 (9.7 %) patients. In patients with early stage 3-year overall survival and progression-free survival were 100 %, in advanced stage – 3-year overall survival – 95 %, progression free survival – 79.7 %. The most common side effects were grade 4 neutropenia in patients treated with BEACOPP-14 / esc (75.0–85.7 %) and peripheral polyneuropathy in patients treated with BV-AVD (45.5 %) which was in most cases reversible. There were no cases of refractoriness and relapse in patients, treated with BV-AVD at the time of analysis.
Conclusion. Results of this study confirm the efficacy of modern chemotherapy regimens and compatible with the results of other large international studies. However, limited acceptance to PET-CT makes it difficult to realize risk-adapted protocols and optimization of treatment intensity. Long-term efficacy assessment requires additional studies with longer follow-up periods in larger population.
Keywords
About the authors
T. N. Aleksandrova
Republican Hospital No. 1 – National Centre of Medicine named after M. E. Nikolaev; North-Eastern Federal University named after M. K. Ammosov
Author for correspondence.
Email: alexandrova_tuyara@mail.ru
ORCID iD: 0000-0002-9940-961X
Russian Federation, 4 Sergelyakhskoye Shosse, Yakutsk 677010; 58 Belinskogo St., Yakutsk 677000
I. A. Bosikov
North-Eastern Federal University named after M. K. Ammosov
Email: alexandrova_tuyara@mail.ru
Russian Federation, 58 Belinskogo St., Yakutsk 677000
U. V. Yadrikhinskaya
Republican Hospital No. 1 – National Centre of Medicine named after M. E. Nikolaev
Email: alexandrova_tuyara@mail.ru
Russian Federation, 4 Sergelyakhskoye Shosse, Yakutsk 677010
I. I. Mulina
Republican Hospital No. 1 – National Centre of Medicine named after M. E. Nikolaev
Email: alexandrova_tuyara@mail.ru
Russian Federation, 4 Sergelyakhskoye Shosse, Yakutsk 677010
V. N. Yadrikhinskaya
North-Eastern Federal University named after M. K. Ammosov
Email: alexandrova_tuyara@mail.ru
Russian Federation, 58 Belinskogo St., Yakutsk 677000
References
- Ministry of Health of Russia. Clinical guidelines. Hodgkin’s lymphoma. Available at: https://cr.minzdrav.gov.ru/view-cr/139_2 (accessed 20.10.2025) (In Russ.)
- Samaneva N.Yu., Lysenko I.B., Nikolaeva N.V. et al. Evolution of drug therapy for classical Hodgkin lymphoma. Yuzhno-Rossiyskiy onkologicheskiy zhurnal = South Russian Journal of Cancer 2022;3(3):41–7. (In Russ.). doi: 10.37748/2686-9039-2022-3-3-5
- Mikhailova N.B. Hodgkin’s lymphoma. Vestnik gematologii = Bulletin of Hematology 2024;20(3):33–58. (In Russ.).
- Ansell S.M. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2022;97(11):1478–88. doi: 10.1002/ajh.26717
- Follows A.M., Santarsieri A. Minimising the toxicities of first line Hodgkin lymphoma treatment in the modern era. Cancers (Basel) 2022;14(21):5390. doi: 10.3390/cancers14215390
- Zaeva G.E., Valiev T.T., Gavrilenko T.F. et al. Long-term effects of pediatric cancer therapy: 35-year clinical experience. Sovremennaya onkologiya = Journal of Modern Oncology 2015;18(1):55–60. (In Russ.).
- Tsaplina N.S., Kozlov A.V., Valiev T.T. et al. Treatment of children with relapsed and refractory classical Hodgkin’s lymphoma: the experience of two centers. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology. 2024;11(3):22–9. (In Russ.). doi: 10.21682/2311-1267-2024-11-3-22-29
- Borchmann P., Ferdinandus J., Schneider G. et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet 2024;404(10450):341–52. doi: 10.1016/S0140-6736(24)01315-1
- Herrera A.F., LeBlanc M., Castellino S.M. et al. Nivolumab + AVD in advanced-stage classic Hodgkin’s lymphoma. N Engl J Med 2024;391(15):1379–89. doi: 10.1056/NEJMoa2405888
- WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edn. Eds.: S.H. Swerdlow, E. Campo, N.L. Harris et al. Lyon, France: IARC, 2017. 585 p.
- Skoetz N., Wil A., Monsef I. et al. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2017;5(5):CD007941. doi: 10.1002/14651858
- Merli F., Luminari S., Gobbi P.G. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 2016;34(11):1175–81. doi: 10.1200/JCO.2015.62.4817
- Behringer K., Mueller H., Goergen H. et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013;31(2):231–9. doi: 10.1002/14651858.cd007941.pub3
- Casasnovas R.O., Bouabdallah R., Brice P. et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 2019;20(2):202–15. doi: 10.1016/S1470-2045(18)30784-8
- Connors J.M., Jurczak W., Straus D.J. et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 2018;378(4):331–44. doi: 10.1056/NEJMoa1708984
Supplementary files
